Cancer-induced Heterogeneous Immunosuppressive Tumor Microenvironments and Their Personalized Modulation

Overview

Journal Int Immunol

Specialty Allergy & Immunology

Date 2016 Jul 13

PMID 27401477

Citations 31

Authors

Tomonori Yaguchi

Yutaka Kawakami

Affiliations

Soon will be listed here.

Abstract

Although recent cancer immunotherapy strategies, including immune-checkpoint blockade (i.e. blocking PD-1, PD-L1 or CTLA-4), have shown durable clinical effects in some (but not all) patients with various advanced cancers, further understanding of human immunopathology, particularly in tumor microenvironments, is essential to improve this type of therapy. The major hurdle for immunotherapy is the immunosuppression that is found in cancer patients. There are two types of immunosuppression: one is induced by gene alterations in cancer; the other is local adaptive immunosuppression, triggered by tumor-specific T cells in tumors. The former is caused by multiple mechanisms via various immunosuppressive molecules and via cells triggered by gene alterations, including activated oncogenes, in cancer cells. The various immunosuppressive mechanisms involve signaling cascades that vary among cancer types, subsets within cancer types and individual cancers. Therefore, personalized immune-interventions are necessary to appropriately target oncogene-induced signaling that modulates anti-cancer immune responses, on the basis of genetic and immunological analysis of each patient. Further understanding of human cancer immunopathology may lead to real improvement of current cancer immunotherapies.

Citing Articles

Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors.

Jo A, Shoji T, Otsuka H, Abe M, Tatsuki S, Chiba Y Int J Clin Oncol. 2025; 30(2):229-240.

PMID: 39812928 DOI: 10.1007/s10147-024-02689-8.

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1.

Wang S, Nie F, Yin Q, Tian H, Gong P, Ju J Cancer Immunol Immunother. 2024; 74(1):22.

PMID: 39535607 PMC: 11561227. DOI: 10.1007/s00262-024-03865-5.

Car T Cells in Solid Tumors: Overcoming Obstacles.

Rojas-Quintero J, Diaz M, Palmar J, Galan-Freyle N, Morillo V, Escalona D Int J Mol Sci. 2024; 25(8).

PMID: 38673757 PMC: 11050550. DOI: 10.3390/ijms25084170.

Interplay between Signaling Pathways and Tumor Microenvironment Components: A Paradoxical Role in Colorectal Cancer.

Ben Hamouda S, Essafi-Benkhadir K Int J Mol Sci. 2023; 24(6).

PMID: 36982677 PMC: 10057671. DOI: 10.3390/ijms24065600.

Clinical cancer immunotherapy: Current progress and prospects.

Liu C, Yang M, Zhang D, Chen M, Zhu D Front Immunol. 2022; 13:961805.

PMID: 36304470 PMC: 9592930. DOI: 10.3389/fimmu.2022.961805.

References

Lee H, Pal S, Reckamp K, Figlin R, Yu H . STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol. 2010; 344:41-59. PMC: 3244828. DOI: 10.1007/82_2010_51. View

Sapkota B, Hill C, Pollack B . Vemurafenib enhances MHC induction in BRAF homozygous melanoma cells. Oncoimmunology. 2013; 2(1):e22890. PMC: 3583938. DOI: 10.4161/onci.22890. View

Yaguchi T, Goto Y, Kido K, Mochimaru H, Sakurai T, Tsukamoto N . Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J Immunol. 2012; 189(5):2110-7. DOI: 10.4049/jimmunol.1102282. View

Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K . Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene. 2004; 23(36):6031-9. DOI: 10.1038/sj.onc.1207812. View

Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y . Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009; 15(3):195-206. DOI: 10.1016/j.ccr.2009.01.023. View

Sumimoto H, Imabayashi F, Iwata T, Kawakami Y . The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med. 2006; 203(7):1651-6. PMC: 2118331. DOI: 10.1084/jem.20051848. View

Spranger S, Bao R, Gajewski T . Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015; 523(7559):231-5. DOI: 10.1038/nature14404. View

Koya R, Mok S, Otte N, Blacketor K, Comin-Anduix B, Tumeh P . BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012; 72(16):3928-37. PMC: 3422880. DOI: 10.1158/0008-5472.CAN-11-2837. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

10.

Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K . Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016; 22(6):679-84. DOI: 10.1038/nm.4086. View

11.

Rimm D, Caca K, Hu G, Harrison F, Fearon E . Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol. 1999; 154(2):325-9. PMC: 1850000. DOI: 10.1016/s0002-9440(10)65278-9. View

12.

Manicassamy S, Reizis B, Ravindran R, Nakaya H, Salazar-Gonzalez R, Wang Y . Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science. 2010; 329(5993):849-53. PMC: 3732486. DOI: 10.1126/science.1188510. View

13.

Kawakami Y, Eliyahu S, Delgado C, Robbins P, Rivoltini L, Topalian S . Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994; 91(9):3515-9. PMC: 43610. DOI: 10.1073/pnas.91.9.3515. View

14.

Chien A, Moore E, Lonsdorf A, Kulikauskas R, Rothberg B, Berger A . Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A. 2009; 106(4):1193-8. PMC: 2626610. DOI: 10.1073/pnas.0811902106. View

15.

Zhu Z, Liu W, Gotlieb V . The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond. Crit Rev Oncol Hematol. 2015; 99:91-9. DOI: 10.1016/j.critrevonc.2015.12.002. View

16.

Ding Y, Shen S, Lino A, Curotto de Lafaille M, Lafaille J . Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells. Nat Med. 2008; 14(2):162-9. DOI: 10.1038/nm1707. View

17.

Robbins P, Li Y, Kawakami Y, Loftus D, Appella E, Rosenberg S . A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996; 183(3):1185-92. PMC: 2192326. DOI: 10.1084/jem.183.3.1185. View

18.

McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S . Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016; 351(6280):1463-9. PMC: 4984254. DOI: 10.1126/science.aaf1490. View

19.

Inozume T, Yaguchi T, Furuta J, Harada K, Kawakami Y, Shimada S . Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. J Invest Dermatol. 2016; 136(1):255-63. DOI: 10.1038/JID.2015.404. View

20.

Ansell S, Lesokhin A, Borrello I, Halwani A, Scott E, Gutierrez M . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2014; 372(4):311-9. PMC: 4348009. DOI: 10.1056/NEJMoa1411087. View